This is an old revision of this page, as edited by Arcadian (talk | contribs) at 20:16, 11 March 2007 ({{Antidepressants}}, added reference, templated existing ref). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 20:16, 11 March 2007 by Arcadian (talk | contribs) ({{Antidepressants}}, added reference, templated existing ref)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.
See also
References
- Kent J (2000). "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression". Lancet. 355 (9207): 911–8. PMID 10752718.
- Fawcett J, Barkin R (1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". J Affect Disord. 51 (3): 267–85. PMID 10333982. link
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |